Everything below concerns clinical endpoint. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
== Licences == SIRIUS is developed by the group of Sebastian Böcker at the FSU Jena in close collaboration with the Bright Giant GmbH. SIRIUS is provided as a software-as-a-service solution. The client software is open-source and installed on the users' computers. Molecular formula annotation using fragmentation trees and isotope pattern analysis is performed on your local computer without subscription requirement. The SIRIUS web services for structural elucidation, including molecular fingerprint prediction, structure database search, confidence score assessment and compound class prediction, require a user account. The web services are free for academic/non-commercial use provided/hosted by the FSU Jena. Academic institutions are identified by their email domain and access will be granted automatically. In some cases, further validation might be required. Bright Giant GmbH offers subscription-based access to the SIRIUS web services for structural elucidation for commercial users.
=== Legal status === United States In the United States, bromazolam was placed under emergency Schedule I status on March 18, 2026, effective until March 18, 2028, with a possible temporary extension or permanent placement. A number of states, such as Virginia, have also placed bromazolam into Schedule 1 at the state level, but this does not include the 6-(2-chlorophenyl) analog phenazolam. Prior to its emergency scheduling, there have been several arrests in the United States for mismarketing bromazolam as alprazolam, typically in the shape of brand name Xanax tablets which constitutes a counterfeit drug charge among others. In August 2021, at least 1 person in Illinois was arrested for "unlawful possession of a controlled substance, a Class 4 felony." for the possession of less than 15 grams (½ oz.) of bromazolam, similar to being charged for unlawful possession of alprazolam in Illinois. It is unknown if this arrest involved counterfeit Xanax shaped tablets or powder. However, bromazolam was not scheduled in Illinois at the time of the arrest. In June 2022, the U.S. Department of Justice reported that bromazolam seizures were "surging" across the United States, driven in part by increasing detections alongside fentanyl. Canada In Canada, illicit opioids such as heroin or fentanyl analogues are mixed with bromazolam and sold at the street level; the product is sometimes referred to as "benzo-dope." United Kingdom In the United Kingdom, bromazolam is a Class C controlled substance.
Examples of important CYP3A4 modulators which are expected to interact with suvorexant include the strong CYP3A4 inhibitors boceprevir, clarithromycin, conivaptan, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, and telithromycin (concomitant use not recommended); the moderate CYP3A4 inhibitors amprenavir, aprepitant, atazanavir, ciprofloxacin, diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, fosamprenavir, grapefruit juice, imatinib, and verapamil (lower doses of suvorexant recommended); and the strong CYP3A4 inducers apalutamide, carbamazepine, efavirenz, enzalutamide, phenytoin, rifampin, and St. John's wort (expected to decrease suvorexant effectiveness). Coadministration of suvorexant with other CNS depressants, such as alcohol, benzodiazepines, opioids, and tricyclic antidepressants, may increase the risk of CNS depression and daytime impairment. Alcohol and suvorexant do not appear to interact in terms of pharmacokinetics but consumption of alcohol in combination with suvorexant is not advised due to additive CNS depression. Dosage adjustment may be necessary when suvorexant is combined with other CNS depressants. Use of suvorexant in combination with other medications used in the treatment of insomnia is not recommended. Suvorexant is not expected to cause clinically meaningful inhibition or induction of various cytochrome P450 enzymes and drug transporters.
Sources: en.wikipedia.org
The various quantities of a particular element involved in the constitution of different molecules are integral multiples of a fundamental quantity that always manifests itself as an indivisible entity and which must properly be named atom. A second objection to atomic theory was philosophical. Scientists in the 19th century had no way of directly observing atoms. They inferred the existence of atoms through indirect observations, such as Dalton's law of multiple proportions. Some scientists adopted positions aligned with the philosophy of positivism, arguing that scientists should not attempt to deduce the deeper reality of the universe, but only systemize what patterns they could directly observe. This generation of anti-atomists can be grouped in two camps. The "equivalentists", like Marcellin Berthelot, believed the theory of equivalent weights was adequate for scientific purposes. This generalization of Proust's law of definite proportions summarized observations. For example, 1 gram of hydrogen will combine with 8 grams of oxygen to form 9 grams of water, therefore the "equivalent weight" of oxygen is 8 grams. These ideas where widely used by chemists without accepting an underlying atomic explanation. The "energeticists", like Ernst Mach and Wilhelm Ostwald, were philosophically opposed to hypothesis about reality altogether. In their view, only energy as part of thermodynamics should be the basis of physical models.
We used to read this same atavistic proclamation by the hellish light of burning Sarajevo, and now we glimpse it again through the flames of the blazing U.S. Embassy in Belgrade, and by the glare of similar but less dramatic arsons set by Serbs in ski masks in northern Kosovo itself. But it needs to be understood that "Serbia" itself has lost nothing and has nothing to complain about. With the independence of Kosovo, the Yugoslav idea is finally and completely dead, but it was Serbian irredentism that killed the last vestige of that idea, and it is to that account that the whole cost ought to be charged. Forget all the nonsense that you may have heard about Kosovo being "the Jerusalem" of Serbia. It may contain some beautiful and ancient Serbian and Serbian Orthodox cultural sites, but it is much more like Serbia's West Bank or Gaza, with a sweltering, penned-up, subject population who were for generations treated as if they were human refuse in the land of their own birth. Nobody who has spent any time in the territory, as I did during and after the eviction of the Serb militias, can believe for a single second that any Kosovar would ever again submit to rule from Belgrade. It's over.
Therapeutic touch (TT), or non-contact therapeutic touch (NCTT), also generically called healing touch, is a pseudoscientific energy therapy which practitioners claim promotes healing and reduces pain and anxiety. "Therapeutic Touch" is a registered trademark in Canada for the "[s]tructured and standardized healing practice performed by practitioners trained to be sensitive to the receiver's energy field that surrounds the body;...no touching is required." Practitioners of therapeutic touch state that by placing their hands on, or near, a patient, they are able to detect and manipulate what they say is the patient's energy field. One highly cited study, designed by the then-nine-year-old Emily Rosa and published in the Journal of the American Medical Association in 1998, found that practitioners of therapeutic touch could not detect the presence or absence of a hand placed a few inches above theirs when their vision was obstructed. Simon Singh and Edzard Ernst concluded in their 2008 book Trick or Treatment that "the energy field was probably nothing more than a figment in the imaginations of the healers". The American Cancer Society noted, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases." A 2004 Cochrane review found no good evidence that it helped with wound healing, but the authors withdrew it in 2016 out of "serious concerns over the validity of included studies".
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。